Results from a randomised phase 3 trial show that the addition of daratumumab to the standard treatment regimen of bortezomib, melphalan, and prednisone improves progression-free survival in patients with multiple myeloma who are ineligible for stem-cell transplantation.
Original Article: [News] Daratumumab for untreated multiple myeloma
NEXT ARTICLE